Ultragenyx Pharmaceutical RARE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$185M-43.9% | -$128.56M+28.7% | -$180.41M-56.9% | -$114.95M+23.9% | -$151M-13.4% | ||
| $8M-8.9% | $8.79M+2.1% | $8.61M0.0% | $8.61M-4.3% | $9M-5.6% | ||
| -$197M-97.3% | -$99.83M-9.2% | -$91.42M+15.9% | -$108.75M+34.5% | -$166M-109% | ||
| $1M+6.6% | $938K-26.6% | $1.28M-54.1% | $2.78M+178% | $1M+513% | ||
| -$49M— | —— | $117.18M+64.9% | $71.07M-40.8% | $120M— | ||
| -$247M-212% | $221.46M+750% | $26.06M-47.3% | $49.49M+210% | -$45M— | ||
| -$198M-96.5% | -$100.77M-8.7% | -$92.7M+16.9% | -$111.53M+33.2% | -$167M-110% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ultragenyx Pharmaceutical generate?
- Ultragenyx Pharmaceutical (RARE) generated -$497.0M in operating cash flow over the trailing twelve months.
- What is Ultragenyx Pharmaceutical's free cash flow?
- After $6.0M of capital expenditures, Ultragenyx Pharmaceutical's free cash flow was -$503.0M over the trailing twelve months, down 27.6% year over year.
- Where does Ultragenyx Pharmaceutical's cash flow data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
